Introduction (O.R. Hommes).
List of Contributors.
1. Pathogenesis of MS - tracking the elusive role of B Lymphocytes (H. Wekerle, A. Iglesias, T. Litzenburger).
2. Genetic susceptibility to multiple sclerosis (A. Compston).
3. HLA controlled susceptibility to multiple sclerosis - a survey (A. Svejgaard).
4. Nordic contributions in multiple sclerosis genetics (J. Hillert).
5. Genomic screening in multiple sclerosis (F. Clerget-Darpoux).
6. Cytokine gene polymorphisms in multiple sclerosis (B.M.J. Uitdehaag).
7. Genetic control of Theiler's virus infection (M. Brahic, S. Aubagnac, L. Behrens, F. Bihl, J.-F. Bureau, S. Vigneau).
8. MHC proteins and human diseases: a tale of recognition in two immune
systems (J.L. Strominger).
9. Central nervous system delivery of therapeutic genes using viral vectors
as an alternative strategy in autoimmune demyelinating diseases (R. Furlan, P.L. Poliani, P. Marconi, E. Brambilla, F. Ruffini, A. Bergami, G. Comi, G. Martino).
10. The contribution of axonal injury to neurologic dysfunction in Theiler's virus-induced inflammatory demyelinating disease (D.R. Ure, D.B. McGavern, S. Sathornsumetee, M. Rodriguez).
11. The effect of virus-like infections on the course of multiple sclerosis (W.A. Sibley).
12. A clinical neuroradiological and virological longitudinal study to verify
the role of virus in inducing relapses in multiple sclerosis patients;
preliminary results (P. Ferrante, R. Mancuso, R. Cavarretta, E. Pagani, M. Filippi, G. Comi, G. Iannucci, P. Melzi, S. Della Bella, D. Caputo).
13. Viral and bacterial specifi cities of oligoclonal IgG bands in multiple
sclerosis (S. Gofette, C.J.M. Sindic).
14. Hepatitis B and multiple sclerosis. Hepatitis B vaccination in France (M. Clanet, D. Brassat).
15. Hepatitis B vaccination and central nervous system demyelination:
an immunological approach (E. Corcuff, J. Reboul, A. Tourbah, G. Edan, O. Gout, O. Lyon-Caen, R. Liblau).
16. Is there a causal link between hepatitis B vaccination and multiple
sclerosis? (P. Monteyne).
17. Public health aspects of hepatitis B vaccination and multiple sclerosis (Ph. Duclos, H. Hall, P. Van Damme).
18. Influenza vaccination in multiple sclerosis (J. De Keyser, G. Ramsaransing, C. Zwanikken).
19. Infection, immunization and immunomodulation - what's the difference? (P. Rieckmann, N. Moriabadi, S. Niewiesk, N. Kruse, K.V. Toyka, V. ter Meulen).
20. Detection of human herpesvirus 6 by quantitative real-time PCR in serum and cerebrospinal fluid of patients with multiple sclerosis (G. Locatelli, M.S. Malnati, D. Franciotta, R. Furlan, G. Comi, G. Martino, P. Lusso).
21. The ability of candidate viruses to explain epidemiological findings in multiple sclerosis (S. Haahr, P. Höllsberg).
22. Active human herpesvirus six viremia in patients with multiple sclerosis (K.K. Knox, J.H. Brewer, D.R. Carrigan).
23. Retroviruses in multiple sclerosis (T. Christensen, P. Dissing Sørensen, H.J. Hansen, A. Møller-Larsen).
24. The role of neuroinvasive human coronaviruses in autoimmune
processes associated with multiple sclerosis (A. Boucher, M. Tremblay, N. Arbour, J. Edwards, R. Day, J. Newcombe, P. Duquette, F. Denis, P.J. Talbot).
25. Association of multiple sclerosis with Chlamydia pneumoniae:
demonstration of the 16S rRNA gene and immunoreactivity of
CSF cationic antibodies against C. pneumoniae antigens (S. Sriram, C.W. Stratton, S. Yao, J.D. Bannan, W.M. Mitchell).
26. A rationale for antiviral therapy in multiple sclerosis (O. Andersen).
27. Antiviral activity of antiherpetic drugs in lymphoblast cells infected
with human herpes virus 6 (L. Naesens, L. De Bolle, E. De Clercq).
28. Il-1 Receptor antagonist: a possible circulating and genetic marker of interferon-beta 1b therapeutic effectiveness in MS (F.L. Sciacca, L.M.E. Grimaldi, G. Comi, N. Canal).
Subject index.